NCT06901609Active, not recruiting
Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients
Source: ClinicalTrials.gov · Last updated 30 Mar 2025
Brief summary (registry, in English)
Heart failure with reduced ejection fraction (HFrEF) is a significant cause of morbidity and mortality. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated efficacy in improving renal outcomes in patients with HFrEF. Pharmacogenetics, the study of how genetic variations influence drug response, could elucidate inter-individual variability in treatment outcomes. This study aims to assess the impact of specific genetic variants on renal outcomes in HFrEF patients treated with SGLT2 inhibitors.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 24 Mar 2025
- Start date
- 22 Nov 2023
- Primary completion date
- 1 Jun 2025
- Lead sponsor
- Ain Shams University
- Diseases
- Heart failure
- NCT number
- NCT06901609
What you commit to
- Study type: Observational
- Planned participants: 200
- From 22 Nov 2023 to the primary completion date, 1 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known hypersensitivity to SGLT2 inhibitors.
- History of ketoacidosis or recurrent urinary tract infections.
- Life expectancy \<6 months due to non-cardiovascular conditions.
Lab values
- End-stage renal disease (eGFR \<30 mL/min/1.73 m²).
Other
- Pregnancy or lactation.
Who the study is looking for
- Adults (≥18 years) with HFrEF (LVEF ≤40%).
- Initiation of SGLT2 inhibitor therapy.
- Stable background HF therapy for at least 4 weeks.
- Written informed consent for participation and genetic testing.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Heart Institute Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.